A recent randomized controlled trial has shown that patients with type 1 diabetes mellitus who are treated with multiple daily insulin injections and continuous glucose monitoring (CGM) enjoy a further improvement in glycaemic control when switched to insulin pump therapy with CGM. However, some increase in biochemical hypoglycaemia was evident with pump treatment.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Battelino, T. et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia 55, 3155–3162 (2012).
Pickup, J. C., Freeman, S. C. & Sutton, A. J. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomized controlled trials using individual patient data. BMJ 343, d3805 (2011).
Beck, R. W. et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA 317, 371–378 (2017).
Lind, M. et al. Continuous glucose monitoring versus conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA 317, 379–387 (2017).
Beck, R. W. et al. Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring (DIAMOND): a multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. http://dx.doi.org/10.1016/S2213-8587(17)30217-6 (2017).
Pickup, J. C. Insulin-pump therapy for type 1 diabetes mellitus. N. Engl. J. Med. 366, 1616–1624 (2012).
Bergenstal, R. M. et al. ASPIRE In-Home Study Group. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N. Engl. J. Med. 369, 224–232 (2013).
Choudhary, P. et al. Hypoglycemia prevention and user acceptance of an insulin pump system with predictive low glucose management. Diabetes Technol. Ther. 18, 288–291 (2016).
Bolinder, J. et al. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomized controlled trial. Lancet 388, 2254–2263 (2016).
Nixon, R., Folwell, R. & Pickup, J. C. Variations in the quality and sustainability of long-term glycaemic control with continuous subcutaneous insulin infusion. Diabet. Med. 31, 1174–1177 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author has received speaker and/or consultancy fees from Cequr, Eli Lilly, Insulet, Medtronic, Novo Nordisk and Roche.
Rights and permissions
About this article
Cite this article
Pickup, J. Insulin pumps after injections and CGM in T1DM. Nat Rev Endocrinol 13, 568–569 (2017). https://doi.org/10.1038/nrendo.2017.108
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2017.108